A confound for the interpretation of these results is the use of a single marker, GFAP, which has increased levels following stroke—which may account for increased length and process measurements that are GFAP+ but not necessarily a change in the total number and length of processes in these astrocytes (if measured using a marker that has unaltered levels following ischemia). The gene discussed is GFAP; the disease is Stroke.